Westminster, Colorado (May 27, 2020) —Flagship Biosciences, providers of expert tissue data insights, today announced that Aymii Couzelis has been named to its executive team as Chief Information Officer. Aymii brings over 20 years of experience leading IT and product development across a range of industries and company sizes, from Fortune 500 corporations to startup companies. As Chief Information Officer, Aymii will work to strengthen Flagship’s ability to dynamically scale technology capabilities throughout the company’s application development, help desk, network engineering, project management, quality assurance, laboratory operations, and data security functions.
Before joining Flagship, Aymii spent more than a decade as CIO for MediFit Corporate Services, a corporate wellness firm. She was previously CEO of ENSOMA and served on the Society of Information Management’s board of directors. At US West Advanced Technologies, Aymii was team lead for the project that created an artificial intelligence-based self-healing infrastructure to repair telephone network problems.
“I am happy to welcome Aymii to Flagship’s executive team, after spending a year with us as a senior technology strategist,” said Trevor Johnson, Flagship Biosciences CEO. “Flagship is poised for significant growth, and Aymii’s experiences in rapidly-evolving, technology-driven industries and with high-profile accounts make her the perfect person to help us achieve our goals.”
“I am thrilled to be a part of the Flagship organization,” said Aymii. “As we expand our scientific processes, machine-learning, laboratory capabilities, and tissue analysis technology, this is an exciting time to join the executive team. I am looking forward to implementing a technology strategy that will enable Flagship to become a world leader in artificial intelligence-based tissue analysis.”
About Flagship Biosciences
Founded in 2009 and headquartered in Westminster, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. It is revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Flagship’s services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability and bringing new insights to tissue analysis results. With expert scientific consultation on every project, Flagship’s team interprets results, contextualizes tissue biology, and identifies the best course for success. www.flagshipbio.com